Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

#2136

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Aim(s): To observe the therapeutic effect and toxicity of CPATEM regimen in the treatment of advanced TNET.

Materials and methods: A total of 10 patients with advanced TNET in China-Japan Friendship Hospital between 2014 and 2017 were treated with capecitabine (750 mg/m2 twice daily, days 1-14) and temozolomide (200 mg/m2 once daily, days 10-14) every 28 days. The response rate, progression-free survival (PFS) and adverse effect after treatment were analyzed. Response rate was calculated by RECIST1.1. Progression-free survival was calculated by the Kaplan-Meier survival method.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,